alexa Antimicrobial Peptides As Novel Alternative Agents For Treatment Of Infectious Diseases | 15140
ISSN: 2155-9597

Journal of Bacteriology & Parasitology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

International Congress on Bacteriology & Infectious Diseases

Margit Mahlapuu
ScientificTracks Abstracts: J Bacteriol Parasitol
DOI: 10.4172/2155-9597.S1.002
Abstract
Bacterial resistance against antibiotic treatment has become a major threat to public health. Antimicrobial peptides (AMPs) have emerged as promising alternative agents for treatment of infectious diseases. Pergamum is a biopharmaceutical company specialized in the development of therapeutic AMPs for local application in infections and wounds. Pergamum has conducted extensive nonclinical and clinical characterization of novel peptides derived from human endogenous proteins as well as marine environment, for their use as anti-infective agents. Synthetic peptides sequentially derived from the AMP centrocin 1, isolated from the green sea urchin, show marked microbicidal and anti-inflammatory properties. Centrocin-1-related peptides also significantly reduced bacterial counts in two different animal models of infected wounds, while Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) failed to develop resistance against these peptides under continued selection pressure. DPK-060 is a chemically synthesized AMP sequentially derived from human kininogen. DPK-060 has a broad antimicrobial activity against gram-positive and gram-negative bacteria, including the strains resistant to conventional antibiotic therapy. In the first phase IIa clinical trial, it was demonstrated that topical application of DPK-060 1% ointment onto eczematous lesions in patients with atopic dermatitis was safe and tolerable. Moreover, DPK-060 was found to reduce the microbial density significantly, as compared to placebo. DPK-060 has also been evaluated for the treatment of acute external otitis. The clinical cure in the group receiving DPK-060 was higher, compared to placebo, and similar or higher compared to the previously reported efficacy evaluation for local antibiotic therapy in the treatment of external otitis.
Biography
Margit Mahlapuu completed her Ph.D. in Molecular and Cell Biology, University of Gothenburg, in 2001. After post-doctoral position at AstraZeneca, Sweden, she has been appointed as project director and chief scientific officer (CSO) of R&D function of several small and mid-sized biotech companies. She has published 30 papers in reputed journals and is inventor of 5 approved patents/pending patent applications. At present, she is CSO of Pergamum AB, and associate Professor in Medicine at the Sahlgrenska Academy, University of Gothenburg.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7